The Influence of Study Design on the Results of Pharmacoepidemiologic Studies of Diabetes Risk With Antipsychotic Therapy

References

• Liebzeit KA, Markowitz JS, Caley CF: New onset diabetes and atyp-ical antipsychotics. Eur Neuropsychopharmacol 2001; 11:25–32
   PubMed Web of Science ®Google Scholar
• Mir S, Taylor D: Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16:63–73
   PubMed Web of Science ®Google Scholar
• Jin H, Meyer JM, Jeste DV: Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associ-ated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002; 14:59–64
   PubMedGoogle Scholar
• Lindenmayer JP, Czobor P. Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290–296
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G: Abnormalities in glucose regulation dur-ing antipsychotic treatment of schizophrenia. Arch Gen Psychia-try 2002; 59:337–345
   PubMed Web of Science ®Google Scholar
• Reinstein M, Sirotovskaya L, Jones L, Mohan S, Chasanov M: Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999; 18:99–104
   Web of Science ®Google Scholar
• Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C: New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003; 59:1–6
   Google Scholar
• Meyer JM: A retrospective comparison of weight, lipid, and glu-cose changes between risperidone- and olanzapine-treated inpa-tients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63:425–433
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63(10):856–865
   PubMed Web of Science ®Google Scholar
• Hedenmalm K, Hagg S, Stahl M, Mortimer 0, Spigset 0: Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25(15):1107–1116
   PubMed Web of Science ®Google Scholar
• Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561–566
   PubMed Web of Science ®Google Scholar
• Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW: Assessment of inde-pendent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325(7358):243–247
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ward A, Levinton C, Robinson K: The risk of diabetes during olanzapine use compared with risperidone use: a retrospec-tive database analysis. J Clin Psychiatry 2002; 63(12):1135–1139
   PubMed Web of Science ®Google Scholar
• Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry 2002; 63(10):920–930
   PubMed Web of Science ®Google Scholar
• Buse JB, Cavazzoni P. Hornbuckle K, Hutchins D, Breier A, Jovanovic L: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56:164–170
   PubMed Web of Science ®Google Scholar
• Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D: Differential effects of antipsychotic agents on the risk of develop-ment of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003; 25:1150–1171
   PubMed Web of Science ®Google Scholar
• Gianfrancesco F, White R, Wang RH, Nasrallah HA: Antipsy-chotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003; 23:328–335
   PubMed Web of Science ®Google Scholar
• Lee D, Fowler R, Kadlubek PJ, Haberman M: No significant dif-ference in diabetes risk during treatment with typical versus atyp-ical antipsychotics: Results from a large observational study. Drug Benefit Trends 2002; 14:46–52
   Google Scholar
• Fuller MA, Shermock KM, Secic M, Grogg AL: Comparative study of development of diabetes mellitus in patients taking ris-peridone and olanzapine. Pharmacotherapy 2003; 23:1037–1043
   PubMed Web of Science ®Google Scholar
• Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, Hardy TA, Hoffmann VP, Hombuckle K, Breier A: Ret-rospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc 2004; 5:38–46
   PubMedGoogle Scholar
• Citrome L, Jaffe A, Levine J, Allingham B, Robinson J: Relationship between antipsychotric medication and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004; 55:1006–1013
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Turrina C, Parrinello G, Brignoli 0, Stefanni G, Mazzaglia G: Incidence of diabetes in a general practic popula-tion: A dabase cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psycho-pharmacol 2005; 20:33–37
   PubMedGoogle Scholar
• Dresselhaus TR, Luck J, Peabody JW: The ethical problem of false positives: A prospective evaluation of physician reporting in the medical record. J Med Ethics 2002; 28:291–294
   PubMed Web of Science ®Google Scholar
• Gruber T, Rudnitsky B: Can we be certain of PRO accuracy and accountability? Inaccurate "report cards" generated by medicare claims data as a marker for laboratory testing in diabetic patients. Am J Med Qual 2002; 17:171–174
   Google Scholar
• Benesch C, Witter DM Jr., Wilder AL, Duncan PW, Samsa GP, Matchar DB: Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease. Neurology 1997; 49: 660–664
   Google Scholar
• Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV: Increased prevalence of type 2 diabetes mellitus among psychi-atric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70:19–26
   PubMed Web of Science ®Google Scholar
• Dixon L, Weiden P. Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26:903–912
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Decina P. Bocola V. Saraceni F, Scapicchio PL: Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37:68–73
   Google Scholar
• Lilliker SL: Prevalence of diabetes in a manic-depressive popula-tion. Compr Psychiatry 1980; 21:270–275
   PubMed Web of Science ®Google Scholar
• Cassidy F, Ahearn E, Carroll BJ: Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychia-try 1999; 156:1417–1420
   PubMed Web of Science ®Google Scholar
• Talbot F, Nouwen A: A review of the relationship between depression and diabetes in adults. Diabetes Care 2000; 23:1556–1562
   PubMed Web of Science ®Google Scholar
• van den Akker M, Schuurman A, Metsemakers J, Buntinx F: Is depression related to subsequent diabetes mellitus? Acta Psychi-atr Scand 2004; 110:78–183
   Google Scholar
• Hosmer D: Applied Logistical Regression. John Wiley & Sons: New York, NY, 1989
   Google Scholar
• Yamada J, Sugimoto Y, Inoue K: Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms. Eur J Pharmacol 1999; 382:211–215
   Google Scholar
• Breum L, Bjerre U, Bak IF, Jacobsen S, Astrup A: Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: Influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 1995; 44(12):1570–1576
   Google Scholar
• Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hyper-tension and antihypertensive therapy as risk factors for type 2 dia-betes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342(13):905–912
   PubMed Web of Science ®Google Scholar
• Luna B, Feinglos MN: Drug-induced hyperglycemia. JAMA 2001; 286(16):1945–1948
   PubMed Web of Science ®Google Scholar
• Russell JD, Johnson GF: Affective disorders, diabetes mellitus and lithium. Aust N Z J Psychiatry 1981; 15:349–353
   Web of Science ®Google Scholar
• Cunningham F, Lambert B, Miller D, et al: Antipsychotic induced diabetes in veteran schizophrenic patients. Presented at: 19th International Conference on, Pharmacoepidemiology, Philadel-phia PA, August 24,2003
   Google Scholar
• Taylor DM, McAskill R: Atypical antipsychotics and weight gain—a systematic review. Acta Psychiatr Scand. 2000; 101:416–432
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore IL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686–1696
   PubMed Web of Science ®Google Scholar